Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer

Academic Article

Abstract

  • © 2020 The Author(s) High-grade serous ovarian cancer (HGSC) patients with no gross residual disease (R0) after primary surgery have the greatest improvement in clinical outcomes. A deep understanding of molecular and cellular heterogeneity of HGSC is lacking. Findings by Lee et al. highlight major molecular and cellular differences between clinically defined subgroups of HGSC.
  • Published In

  • Cell Reports  Journal
  • Digital Object Identifier (doi)

    Author List

  • Lee S; Zhao L; Rojas C; Bateman NW; Yao H; Lara OD; Celestino J; Morgan MB; Nguyen TV; Conrads KA
  • Volume

  • 31
  • Issue

  • 2